Earnings summaries and quarterly performance for MNMD.
Executive leadership at MNMD.
Board of directors at MNMD.
Research analysts who have asked questions during MNMD earnings calls.
SK
Sumant Kulkarni
Canaccord Genuity
5 questions for MNMD
Also covers: ACAD, ATAI, BTAI +7 more
Michael Okunewitch
Maxim Group
4 questions for MNMD
Also covers: BLFS, BLTE, BNGO +11 more
RL
Rudy Li
Chardan Capital Markets
4 questions for MNMD
Also covers: PRAX, PRTA, STOK
Brian Abrahams
RBC Capital Markets
3 questions for MNMD
Also covers: ACAD, ATAI, BCRX +17 more
CD
Charles Duncan
Cantor Fitzgerald & Co.
3 questions for MNMD
Also covers: ACAD, ALKS, ATAI +12 more
MG
Marc Goodman
Leerink Partners
3 questions for MNMD
Also covers: ACAD, ALDX, ALKS +14 more
Christopher Chen
Baird
2 questions for MNMD
EG
Elias Georgas
Canaccord Genuity Group
2 questions for MNMD
Gavin Clark-Gartner
Evercore ISI
2 questions for MNMD
Also covers: ACRS, ARGX, ASND +11 more
Jay Olson
Oppenheimer & Co. Inc.
2 questions for MNMD
Also covers: ACAD, AMGN, BIIB +22 more
JB
Joel Beatty
Baird
2 questions for MNMD
Also covers: ACAD, ALKS, AMLX +11 more
LS
Luis Santos
H.C. Wainwright & Co.
2 questions for MNMD
Also covers: CMPS, HRMY, ONCY +1 more
Patrick Trucchio
H.C. Wainwright & Co.
2 questions for MNMD
Also covers: ALT, ARWR, ATAI +13 more
PS
Pete Stavropoulos
Cantor Fitzgerald
2 questions for MNMD
Also covers: ABOS, ALEC, ARCT +7 more
FB
François Brisebois
Oppenheimer & Co. Inc.
1 question for MNMD
Also covers: ACHV, AQST, AVDL +11 more
JN
James Nevin
RBC Capital Markets
1 question for MNMD
Jason McCarthy
Maxim Group
1 question for MNMD
Also covers: BCLI, BRTX, CHRS +10 more
MY
Madhumita Yennawar
Leerink Partners
1 question for MNMD
Also covers: EOLS
Recent press releases and 8-K filings for MNMD.
MindMed (Definium Therapeutics) Provides Update on DT120 Phase III Progress and Commercial Strategy
MNMD
New Projects/Investments
Guidance Update
Product Launch
- MindMed, recently rebranded as Definium Therapeutics, is progressing its lead product, DT120 (LSD/lysurgide), through Phase III clinical trials for Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD).
- The company expects three pivotal Phase III readouts in 2026: two for GAD (Voyage and Panorama) and one for MDD (EMERGE), with a second MDD study (Ascend) commencing mid-year.
- Earlier Phase II data for DT120 in GAD showed a 0.81 effect size, rapid onset, 12-week durability, and a 48% remission rate, which contributed to its Breakthrough Therapy Designation in 2024.
- MindMed targets a substantial market of 50 million U.S. adults impacted by anxiety and depression, and secured $250 million in October 2025 to accelerate commercial readiness and its second MDD study.
- Commercial preparations are underway, including a comprehensive launch plan, targeting model, and market access strategy, with potential pricing for DT120 benchmarked against Spravato's $28,000-$70,000 annual cost.
Jan 14, 2026, 10:15 PM
Definium Therapeutics (MNMD) Provides Update on DT120 Phase 3 Program and Commercialization Strategy
MNMD
Product Launch
New Projects/Investments
- Definium Therapeutics (MNMD), recently rebranded, is focused on advancing DT120 (lysurgide) for Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD).
- The company anticipates three pivotal Phase 3 readouts in 2026: the first for GAD in Q2 2026, an MDD trial mid-year, and a second GAD trial in the second half of the year. A fourth Phase 3 MDD study is also scheduled to begin around mid-year 2026.
- Phase 2 data for GAD demonstrated a rapid and durable effect with an effect size of 0.81 and a 48% remission rate after a single dose, which led to breakthrough therapy designation.
- Definium sees an extraordinary market opportunity with 50 million U.S. adults impacted by anxiety and depression, and recently raised $250 million in October 2025 to accelerate commercial preparedness and clinical development.
Jan 14, 2026, 10:15 PM
Definium Therapeutics (formerly MindMed) provides update on DT120 clinical trials and commercial strategy
MNMD
New Projects/Investments
Guidance Update
Product Launch
- Definium Therapeutics, formerly known as MindMed, is focused on developing DT120 (LSD/lysurgide) for generalized anxiety disorder (GAD) and major depressive disorder (MDD).
- The company anticipates three pivotal Phase 3 readouts in 2026: two for GAD (Voyage and Panorama) and one for MDD (Merge). The first readout is expected in Q2 2026, the MDD trial mid-year, and the second GAD readout in H2 2026. A fourth Phase 3 study (Ascend) in MDD is scheduled to begin mid-year 2026.
- DT120 demonstrated compelling Phase 2 data in GAD, showing a 0.81 effect size and a 48% remission rate at 12 weeks after a single dose, which led to breakthrough therapy designation.
- Definium Therapeutics raised $250 million in October 2025 to accelerate commercial preparedness, NDA activities, and the second MDD study. The company is actively building a comprehensive launch plan and targeting model, benchmarking potential annual pricing against Spravato's $28,000-$70,000 per patient.
Jan 14, 2026, 10:15 PM
MindMed Provides Business Update and Anticipated Milestones
MNMD
Guidance Update
New Projects/Investments
- MindMed (MNMD) reported ~$412 million in cash, cash equivalents, and investments as of December 31, 2025, providing a cash runway expected to extend into 2028.
- The company's lead asset, DT120 ODT, is in four Phase 3 studies for Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD), with three Phase 3 readouts anticipated in 2026. Specifically, topline readouts for GAD studies (Voyage and Panorama) are expected in 2Q 2026 and 2H 2026, respectively, and for the MDD Emerge study in Mid 2026.
- DT120 ODT has demonstrated a statistically significant dose response in Phase 2b, with the optimal 100 µg dose showing a 21.9-point improvement on the HAM-A at Week 12 and 48% remission rate in GAD, and has received FDA Breakthrough Therapy Designation.
- The company projects a potential annual revenue opportunity of $2.8B to $7.0B per 100,000 patients for DT120 ODT, targeting approximately 27.0 million US adults with GAD or MDD.
- MindMed initiated a Phase 2a study for DT402 in Autism Spectrum Disorder (ASD) in Q4 2025, with initial data expected in 2026.
Jan 12, 2026, 7:45 PM
Definium Therapeutics announces rebranding, pipeline milestones, and financial position
MNMD
New Projects/Investments
Guidance Update
- Mind Medicine (MindMed) Inc. has rebranded to Definium Therapeutics, Inc., with its Nasdaq ticker symbol changing from MNMD to DFTX effective January 13, 2026.
- The company anticipates three Phase 3 readouts in 2026 for its lead candidate, DT120 ODT, which is being developed for Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD). Topline data from the Voyage study (GAD) is expected in 2Q 2026, Panorama (GAD) in 2H 2026, and Emerge (MDD) mid-year 2026.
- As of December 31, 2025, Definium Therapeutics reported estimated preliminary cash, cash equivalents, and investments of approximately $412 million. These funds are expected to support operations into 2028.
Jan 12, 2026, 1:24 PM
Mind Medicine Details Development and Commercialization Strategy for 120 in MDD and GAD
MNMD
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Mind Medicine is pursuing a broad label for 120 (a D-tartrate salt of LSD) in Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD), aiming to maximize market opportunity and patient impact.
- In its Phase 2b study for GAD, 120 demonstrated the largest absolute and placebo-adjusted magnitude of change ever seen in anxiety, with 48% of severe GAD patients achieving remission after a single treatment, and showed rapid and durable anxiolytic and antidepressant effects.
- The company has selected a 100 microgram dose for its Phase 3 studies in GAD and MDD, based on Phase 2 data showing optimal efficacy without increased adverse event burden compared to higher doses.
- Mind Medicine plans to initially target existing Spravato centers for commercialization but intends to aggressively expand its reach given the broad label and significant patient need, with ongoing discussions regarding payer access.
Dec 3, 2025, 8:00 PM
Mind Medicine Outlines Clinical Development and Commercialization Strategy for 120
MNMD
New Projects/Investments
Product Launch
- Mind Medicine is pursuing a broad label for its drug 120 in Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD), a strategy intended to maximize market opportunity and patient impact, differentiating from competitors who focused on Treatment-Resistant Depression (TRD).
- In its Phase 2b study for GAD, 120 demonstrated a 48% remission rate in patients with severe GAD after a single treatment over a 12-week observation period, exhibiting rapid and durable anxiolytic and antidepressant effects.
- The company has selected the 100 microgram dose for its Phase 3 studies in both GAD and MDD, based on Phase 2 data that showed optimal efficacy without increased adverse events compared to higher doses.
- For commercialization, Mind Medicine plans to leverage existing infrastructure, such as Spravato centers, for initial targeting while also pursuing a broader, more expansive strategy over time to support widespread adoption of 120.
Dec 3, 2025, 8:00 PM
Mind Medicine Discusses MM-120 Development and Commercialization Strategy
MNMD
Product Launch
New Projects/Investments
- Mind Medicine is pursuing a broad development path for MM-120 (LSD D-tartrate salt) in Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD), aiming for a wider label to address significant patient needs.
- Phase IIB results for MM-120 in GAD demonstrated the largest absolute and placebo-adjusted magnitude of change ever seen in anxiety, with rapid (within 24 hours) and durable effects lasting 12 weeks; no suicidal ideation was observed.
- The 100 microgram dose was selected for Phase III studies in GAD and MDD due to its optimal efficacy and favorable benefit-risk profile, with three readouts anticipated next year across both programs.
- Antidepressant effects observed in the GAD Phase IIB study provided confidence to advance MM-120 into an MDD program.
- Mind Medicine's commercialization strategy will initially leverage existing Spravato centers for their infrastructure and patient base, with plans for aggressive expansion over time.
Dec 3, 2025, 8:00 PM
MindMed Provides Update on MM120 Clinical Development and Commercial Strategy
MNMD
New Projects/Investments
Guidance Update
- MindMed's lead program, MM120, an LSD ODT formulation for generalized anxiety disorder (GAD) and major depressive disorder (MDD), received Breakthrough Therapy Designation in 2024.
- The company anticipates three pivotal readouts in 2026: two for GAD and one for MDD, with the first MDD readout now expected in mid-2026.
- Management suggests a four-point or better delta on HAM-A for GAD and MADRS for MDD would constitute a "great" or "really positive" outcome in their respective Phase 3 trials.
- MindMed intends to file with two GAD studies and plans to leverage existing Spravato infrastructure for commercialization, with expected patient monitoring requirements of six to eight hours.
- A recent financing round was conducted to accelerate NDA writing, KOL education, and state prioritization, positioning the company for a significant year in 2026.
Dec 2, 2025, 5:30 PM
MindMed Discusses MM120 Development and 2026 Milestones
MNMD
New Projects/Investments
Guidance Update
- MindMed's lead program, MM120, an ODT formulation of LSD, is in development for Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD).
- The company anticipates three pivotal data readouts in 2026 (two for GAD, one for MDD) and will launch a second pivotal study for MDD. The first depression readout has been pulled forward to mid-2026.
- Regulatory interactions with the FDA have been "remarkably positive", leading to a Breakthrough Therapy Designation in 2024.
- For GAD Phase III, MindMed expects a positive statistical outcome with a clinically meaningful effect in the 3 to 3.5 point range, with a four-point delta or better considered a strong result. For MDD, a four-point or better outcome is desired.
- MindMed recently conducted a financing round to accelerate NDA writing, KOL education, and state prioritization, positioning the company for a significant 2026.
Dec 2, 2025, 5:30 PM
Quarterly earnings call transcripts for MNMD.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more